The Limitations Paragraph: The Most Informative Section of the Report, and the Least Read
The Limitations Paragraph: The Most Informative Section of the Report, and the Least Read
It looks like the terms and conditions of the document, so it gets skipped. It is in fact the only part of the report that describes the test rather than the patient — and the one place the laboratory is obliged to tell you where its own assay is weakest.
Near the end of every genetic test report, usually in smaller type, there is a block of text most readers treat as legal furniture. It has the cadence of a terms-and-conditions notice. It appears to say the same thing on every report, and it appears to have been written by someone protecting the laboratory rather than informing the person holding the page. So it gets skipped.
Half of that reading is correct. It is close to identical on every report a given laboratory issues for a given test. But that is the fact being misinterpreted, not the reason to skip it. Everything else on the report is about one patient — the variants found, how they were classified, what the laboratory thinks they mean. The limitations section is the only part that describes the test: what it can see, what it cannot, and how well. It is a specification sheet, filed under a heading that makes it look like a waiver.
What professional standards actually require to be there
The reason the section is worth reading is not legal. It is regulatory. Professional standards specify what has to go in it, and the requirements are more revealing than the format suggests.
The ACMG technical standard for diagnostic gene panels states the obligation directly: it is the laboratory's responsibility to identify, in a disclaimer or limitations section, the regions and exons that performed poorly or inconsistently during test validation. If genes or regions were deliberately excluded — because a different assay is considered first-tier for them, or because a neighbouring pseudogene makes them unreliable — that exclusion has to be specified. Technical limits on detecting large deletions and duplications, and on non-coding variants, are to be explained in detail rather than gestured at.1 The 2021 ACMG standard for next-generation sequencing adds the corollary: clinically relevant regions that cannot be assayed reliably by sequencing — areas of homology, low complexity, or methylation-dependent conditions — should be routed to ancillary assays.2 ACMG's laboratory standards are blunter still on one point in particular: sequencing will not detect large gene deletions or duplications, and where the test does not cover promoter or intragenic regions, that has to be clearly stated.6
Read that from the receiving end. The section that looks like the laboratory covering itself is the section where the laboratory is required to write down where its own test is weakest. It is a disclosure obligation wearing the costume of a disclaimer.
| What the report says | What it means for this patient |
|---|---|
| Does not detect copy-number changes below n exons | A deletion or duplication in your candidate gene was never in scope. It needs a separate order, not a reinterpretation |
| Low-coverage regions available on request | The laboratory holds a gap list specific to this specimen and will release it. Ask before ordering anything else |
| Minimum validated allele fraction | Below that threshold a genuine variant reads as absent. Decisive for mosaicism, low tumor content, and treated samples |
| Homologous regions and pseudogene loci not assessed | Named gene families are effectively invisible to this method and need an orthogonal assay |
| Classifications reflect current evidence | The report has a shelf life. This is the sentence that authorises a reanalysis request later |
| Developed by the laboratory; not FDA-cleared | A statement about regulatory pathway, not about quality. See below |
The sentence everyone misreads
The most misread line in a clinical genomic report is the one about the FDA. Read quickly, this test has not been cleared or approved by the FDA sounds like an admission that the assay is unproven. It is not. It describes which regulatory route the test travelled.
Under CLIA, a laboratory-developed test must establish accuracy, precision, reportable range, reference range, analytical sensitivity — the limit of detection — and analytical specificity before it is used clinically, and the laboratory is inspected against that evidence.3 Analytical sensitivity is not a single tidy number for a test of this kind, either: ACMG's standards note that the conventional definition does not fit genome-scanning methods, which can turn up variants nobody has classified, so laboratories document detection of known variants and extrapolate across the region analysed.5 The disclaimer is telling you the test was validated by the laboratory and is overseen through CLIA, rather than reviewed by the FDA before marketing. That is a genuine distinction, and one worth understanding. It is not a confidence rating.
The boundary has also been in open dispute. The FDA's 2024 rule bringing laboratory-developed tests under medical-device regulation was vacated in full by a federal district court on 31 March 2025, and in September 2025 the FDA issued a rule reverting the regulation to its earlier text.4 The disclaimer's wording did not change through any of it — a fair illustration of how little that sentence says about the test, and how much it says about the system the test sits inside.
Read it once per assay, not once per patient
Here is the practical consequence of the very thing that makes the section look skippable. Because it is boilerplate — because it is identical across every report that laboratory issues for that assay — you only have to read it once.
Read it properly the first time you order a given test from a given laboratory. Extract the four or five facts that actually bear on your patients: which variant classes are out of scope, what the detection floor is, which genes the method cannot resolve, and whether the gap list is available. Write them down. Every subsequent report from that assay then arrives pre-interpreted, and you never again have to wonder whether no pathogenic variant detected included copy-number changes.
Most clinicians order repeatedly from a small number of laboratories. That makes this one of the highest-leverage quarter-hours in the entire workflow. The section's genericness is not the reason to skip it — it is the reason the investment only has to be made once.
Three questions to ask
- Which variant classes does this assay not detect, and what would I order to cover them? Ask the laboratory director or the genetic counsellor. The answer is a short, stable list, and it applies to every patient you send them.
- Can you send the low-coverage region list for this specimen? Most laboratories generate it and will release it on request. It turns a generic caveat into a specific statement about the patient in front of you.
- What is the lowest allele fraction this assay reliably calls? If you are looking for mosaicism, a low-purity tumour, or disease in a treated sample, this number decides whether a negative result means anything at all.
The limitations paragraph is written in the register of a disclaimer and functions as a specification. It is the one section where the laboratory states what it cannot do — which makes it the only part of the report that says anything about the answers you did not receive.
References
- Diagnostic gene sequencing panels: from design to report — a technical standard of the American College of Medical Genetics and Genomics. Genetics in Medicine, 2020. sciencedirect.com
- Next-generation sequencing for constitutional variants in the clinical laboratory, 2021 revision: a technical standard of the ACMG. Genetics in Medicine, 2021. sciencedirect.com
- Guidelines for validation of next-generation sequencing-based oncology panels: a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists. Journal of Molecular Diagnostics, 2017. sciencedirect.com
- Laboratory Developed Tests — regulatory status, including the 31 March 2025 vacatur and the September 2025 rescission rule. U.S. Food and Drug Administration. fda.gov
- ACMG clinical laboratory standards for next-generation sequencing. Genetics in Medicine, 2013. nature.com
- ACMG Technical Laboratory Standards, Section G: clinical molecular genetics — sequencing, and the reporting of regions not covered. American College of Medical Genetics and Genomics. acmg.net